Trial Outcomes & Findings for Bioenergetic Alterations After Exenatide Administration (NCT NCT00623545)

NCT ID: NCT00623545

Last Updated: 2015-01-09

Results Overview

Energy intake is as calculated from energy expenditure as measured by doubly labeled water and change in body energy stores before and at the end of treatment. Units are kcal/d.

Recruitment status

COMPLETED

Study phase

PHASE4

Target enrollment

28 participants

Primary outcome timeframe

3 months

Results posted on

2015-01-09

Participant Flow

Recruitment period was ca. 5/1/2008 to 6/30/2010. Subjects were recruited through local advertisements

Subjects were not entered if they failed to meet entry criteria or failed to attend informational appointment

Participant milestones

Participant milestones
Measure
Single Arm Study of Exenatide Treatment
Subjects serve as their own controls. Measures of outcome variables are made before treatment and again at the end of the1 treatment period made. Outcomes are based on the change in these variables.
Overall Study
STARTED
28
Overall Study
COMPLETED
18
Overall Study
NOT COMPLETED
10

Reasons for withdrawal

Reasons for withdrawal
Measure
Single Arm Study of Exenatide Treatment
Subjects serve as their own controls. Measures of outcome variables are made before treatment and again at the end of the1 treatment period made. Outcomes are based on the change in these variables.
Overall Study
Adverse Event
6
Overall Study
Withdrawal by Subject
4

Baseline Characteristics

Bioenergetic Alterations After Exenatide Administration

Baseline characteristics by cohort

Baseline characteristics by cohort
Measure
Single Arm Study of Exenatide Treatment
n=28 Participants
Subjects serve as their own controls. Measures of outcomes are performed before and at the end of treatment. Outcomes are based on the change in the variables.
Age, Categorical
<=18 years
0 Participants
n=99 Participants
Age, Categorical
Between 18 and 65 years
28 Participants
n=99 Participants
Age, Categorical
>=65 years
0 Participants
n=99 Participants
Age, Continuous
40 years
STANDARD_DEVIATION 10 • n=99 Participants
Sex: Female, Male
Female
18 Participants
n=99 Participants
Sex: Female, Male
Male
10 Participants
n=99 Participants
Region of Enrollment
United States
28 participants
n=99 Participants

PRIMARY outcome

Timeframe: 3 months

Population: Those that completed baseline and final measurements.

Energy intake is as calculated from energy expenditure as measured by doubly labeled water and change in body energy stores before and at the end of treatment. Units are kcal/d.

Outcome measures

Outcome measures
Measure
Exenitide Treatment
n=18 Participants
There is one treatment arm. Subjects serve as their own controls for the outcome measure. The measures are made before the treatment is started at during the end of the treatment.
Change in Energy Intake Measured Before Treatment and at the End of Treatment.
-167 kcal/d
Standard Deviation 173

SECONDARY outcome

Timeframe: 3 months

Body weight after overnight fast in light clothing

Outcome measures

Outcome measures
Measure
Exenitide Treatment
n=18 Participants
There is one treatment arm. Subjects serve as their own controls for the outcome measure. The measures are made before the treatment is started at during the end of the treatment.
Weight Loss After Administration of Exenatide.
-2.0 kg
Standard Deviation 2.8

Adverse Events

Single Arm Study of Exenatide Treatment

Serious events: 0 serious events
Other events: 6 other events
Deaths: 0 deaths

Serious adverse events

Adverse event data not reported

Other adverse events

Other adverse events
Measure
Single Arm Study of Exenatide Treatment
n=28 participants at risk
Gastrointestinal disorders
nausea
17.9%
5/28 • Number of events 5 • 3 months
periodic self-report
Psychiatric disorders
claustrophobia
3.6%
1/28 • Number of events 1 • 3 months
periodic self-report

Additional Information

Dale A Schoeller

University of Wisconsin-Madison

Phone: 608-262-1082

Results disclosure agreements

  • Principal investigator is a sponsor employee
  • Publication restrictions are in place